MoonLake announced on Monday, June 22, 2026, the Week 52 results from its Phase 3 VELA program, which is evaluating the drug candidate sonelokimab for the treatment of hidradenitis suppurativa (HS). The data, released by the biotechnology company, offers a comprehensive look at the drug’s performance over a full year of treatment.
Financial and healthcare news outlets have reported on the response-rate figures derived from MoonLake’s official release. These reports summarize the clinical development update, emphasizing that the information presented is not intended as medical advice. The company’s disclosures maintain necessary clinician caveats regarding the study’s current status.
Hidradenitis suppurativa is a chronic inflammatory skin condition characterized by recurrent, painful nodules, abscesses, and sinus tracts, primarily affecting areas with apocrine sweat glands such as the armpits, groin, and under the breasts. The VELA program is designed to assess the long-term efficacy and safety of sonelokimab in patients diagnosed with moderate to severe HS.
While the Week 52 data provides insights into the drug’s potential, it is crucial to note that these are results from an ongoing clinical trial. The company’s communications have carefully avoided implying that sonelokimab has received regulatory approval or that it represents a definitive cure or readily available treatment beyond the scope of the reported study parameters. The focus remains on the data generated within the controlled environment of the clinical trial.
Further analysis of the Week 52 data is expected to inform subsequent stages of drug development and regulatory submissions. The company’s commitment to transparency in reporting clinical trial outcomes is a standard practice in the pharmaceutical industry, allowing for informed evaluation by healthcare professionals and researchers. The results from the VELA program are a significant step in the long process of bringing new therapeutic options to patients suffering from chronic conditions like hidradenitis suppurativa.
This clinical-development update is part of a broader effort within the pharmaceutical sector to address unmet medical needs through rigorous scientific investigation and data-driven reporting. The ongoing evaluation of sonelokimab’s profile underscores the complexities and lengthy timelines inherent in drug discovery and development, particularly for chronic and often debilitating diseases.
